Olema Pharmaceuticals, Inc.
OLMAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Olema Pharmaceuticals, Inc. (OLMA) is listed under Biotechnology. The $1.00B market capitalization puts OLMA squarely in small-cap range for its industry. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Market Cap
$1.00B
Beta
2.01
P/E (TTM)
—
P/E (Fwd)
-4.62
EPS (TTM)
$-2.03
EPS (Fwd)
$-2.48
ROE
-42.9%
ROA
-25.5%
Cash
$505.3M
Total Debt
$4.0M
Free CF
-$78.8M
52W Change
160.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $505.3M in cash comfortably exceeding the $4.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$78.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -42.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Olema Pharmaceuticals, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, OLMA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Olema Pharmaceuticals, Inc. and its sector.